CIP2A expression predicts recurrences of tamoxifen-treated breast cancer
CIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade and therapeutic resistance. CIP2A drives an oncogenic potential through inhibiting protein phosphatase 2A, stabilizing MYC, and promoting epithelial-to-mesenchymal transit...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-10-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317722064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850058072756584448 |
|---|---|
| author | Shawn Baldacchino Laura M Wastall Christian Saliba Thomas A Hughes Christian Scerri Angelene Berwick Valerie Speirs Andrew M Hanby Godfrey Grech |
| author_facet | Shawn Baldacchino Laura M Wastall Christian Saliba Thomas A Hughes Christian Scerri Angelene Berwick Valerie Speirs Andrew M Hanby Godfrey Grech |
| author_sort | Shawn Baldacchino |
| collection | DOAJ |
| description | CIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade and therapeutic resistance. CIP2A drives an oncogenic potential through inhibiting protein phosphatase 2A, stabilizing MYC, and promoting epithelial-to-mesenchymal transition, although further biological mechanisms for CIP2A are yet to be defined. CIP2A protein expression was studied by immunohistochemistry in oestrogen receptor–positive primary breast cancers (n = 250) obtained from the Leeds Tissue Bank. In total, 51 cases presented with a relapse or metastasis during adjuvant treatment with tamoxifen and were regarded as tamoxifen resistant. CIP2A expression was scored separately for cytoplasmic, nuclear, or membranous staining, and scores were tested for statistically significant relationships with clinicopathological features. Membranous CIP2A was preferentially expressed in cases who experienced a recurrence during tamoxifen treatment thus predicting a worse overall survival (log rank = 8.357, p = 0.004) and disease-free survival (log rank = 21.766, p < 0.001). Cox multivariate analysis indicates that it is an independent prognostic indicator for overall survival (hazard ratio = 4.310, p = 0.013) and disease-free survival (hazard ratio = 5.449, p = 0.002). In this study, we propose the assessment of membranous CIP2A expression as a potential novel prognostic and predictive indicator for tamoxifen resistance and recurrence within oestrogen receptor–positive breast cancer. |
| format | Article |
| id | doaj-art-d72e184faeaa4b3fa5a411820ccf90f4 |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-d72e184faeaa4b3fa5a411820ccf90f42025-08-20T02:51:15ZengSAGE PublishingTumor Biology1423-03802017-10-013910.1177/1010428317722064CIP2A expression predicts recurrences of tamoxifen-treated breast cancerShawn Baldacchino0Laura M Wastall1Christian Saliba2Thomas A Hughes3Christian Scerri4Angelene Berwick5Valerie Speirs6Andrew M Hanby7Godfrey Grech8Laboratory of Molecular Pathology, Department of Pathology, Faculty of Medicine & Surgery, University of Malta, Msida, MaltaDepartment of Cellular Pathology, St James’s University Hospital, Leeds, UKCentre for Molecular Medicine and Biobanking, University of Malta, Msida, MaltaSchool of Medicine, University of Leeds, Leeds, UKDepartment of Physiology & Biochemistry, Faculty of Medicine & Surgery, University of Malta, Msida, MaltaLeeds Institute of Cancer & Pathology, Faculty of Medicine and Health, University of Leeds, Leeds, UKLeeds Institute of Cancer & Pathology, Faculty of Medicine and Health, University of Leeds, Leeds, UKLeeds Institute of Cancer & Pathology, Faculty of Medicine and Health, University of Leeds, Leeds, UKLaboratory of Molecular Pathology, Department of Pathology, Faculty of Medicine & Surgery, University of Malta, Msida, MaltaCIP2A is emerging as an oncoprotein overexpressed commonly across many tumours and generally correlated with higher tumour grade and therapeutic resistance. CIP2A drives an oncogenic potential through inhibiting protein phosphatase 2A, stabilizing MYC, and promoting epithelial-to-mesenchymal transition, although further biological mechanisms for CIP2A are yet to be defined. CIP2A protein expression was studied by immunohistochemistry in oestrogen receptor–positive primary breast cancers (n = 250) obtained from the Leeds Tissue Bank. In total, 51 cases presented with a relapse or metastasis during adjuvant treatment with tamoxifen and were regarded as tamoxifen resistant. CIP2A expression was scored separately for cytoplasmic, nuclear, or membranous staining, and scores were tested for statistically significant relationships with clinicopathological features. Membranous CIP2A was preferentially expressed in cases who experienced a recurrence during tamoxifen treatment thus predicting a worse overall survival (log rank = 8.357, p = 0.004) and disease-free survival (log rank = 21.766, p < 0.001). Cox multivariate analysis indicates that it is an independent prognostic indicator for overall survival (hazard ratio = 4.310, p = 0.013) and disease-free survival (hazard ratio = 5.449, p = 0.002). In this study, we propose the assessment of membranous CIP2A expression as a potential novel prognostic and predictive indicator for tamoxifen resistance and recurrence within oestrogen receptor–positive breast cancer.https://doi.org/10.1177/1010428317722064 |
| spellingShingle | Shawn Baldacchino Laura M Wastall Christian Saliba Thomas A Hughes Christian Scerri Angelene Berwick Valerie Speirs Andrew M Hanby Godfrey Grech CIP2A expression predicts recurrences of tamoxifen-treated breast cancer Tumor Biology |
| title | CIP2A expression predicts recurrences of tamoxifen-treated breast cancer |
| title_full | CIP2A expression predicts recurrences of tamoxifen-treated breast cancer |
| title_fullStr | CIP2A expression predicts recurrences of tamoxifen-treated breast cancer |
| title_full_unstemmed | CIP2A expression predicts recurrences of tamoxifen-treated breast cancer |
| title_short | CIP2A expression predicts recurrences of tamoxifen-treated breast cancer |
| title_sort | cip2a expression predicts recurrences of tamoxifen treated breast cancer |
| url | https://doi.org/10.1177/1010428317722064 |
| work_keys_str_mv | AT shawnbaldacchino cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT lauramwastall cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT christiansaliba cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT thomasahughes cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT christianscerri cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT angeleneberwick cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT valeriespeirs cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT andrewmhanby cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer AT godfreygrech cip2aexpressionpredictsrecurrencesoftamoxifentreatedbreastcancer |